Story excerpt provided by Crain’s Cleveland Business .
Written by Scott Suttell.
BioMotiv, a Shaker Heights-based drug development accelerator associated with The Harrington Project, and the University of Pittsburgh have launched a company that focuses on treating inflammatory diseases.
The startup, Koutif Therapeutics, is developing a small-molecule, oral inhibitor of an E3 ligase, Fbxo3, to treat conditions such as neuropathic pain, chronic obstructive pulmonary disease (COPD), lung transplant rejection and irritable bowel disease, BioMotiv said in a news release.
Koutif is based on intellectual property licensed from the University of Pittsburgh and the U.S. Department of Veterans Affairs. The technology was developed by Dr. Rama K. Mallampalli, a Harrington Scholar from the University of Pittsburgh Medical Center, and Beibei Chen, Ph.D, director of the Small Molecule Therapeutic Center.
Click here to read the complete article.
Originally published September 22, 2017.